This Perspective is a continuation of our analysis of US FDA-approved small-molecule drugs
(1938–2012) containing nitrogen heterocycles. In this study we report drug structure and …

Mechanical circulatory support (MCS) evolved from an engineering dream to clinical reality
during the 1980s when increasing numbers of patients were dying on heart transplant wait …

Budd-Chiari syndrome and non-cirrhotic non-tumoral portal vein thrombosis are 2 rare
disorders, with several similarities that are categorized under the term splanchnic vein …

Heart failure (HF) is one of the major causes of death worldwide. Despite the high incidence
of stroke in patients with HF, there has been a controversy as to whether HF itself is a risk …

Activated coagulation factor XI (FXIa) is a highly attractive antithrombotic target as it
contributes to the development and progression of thrombosis but is thought to play only a …

Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation
that are required for hemostasis. However, aberrant activation of coagulation can lead to …

Factor XIa is a plasma serine protease that contributes to thrombin generation primarily
through proteolytic activation of factor IX. Traditionally considered part of the intrinsic …

The Vitamin K antagonist warfarin was the only oral anticoagulant available for decades for
the treatment of thrombosis and prevention of thromboembolism until Direct Oral …

Vitamin K-antagonists (VKA) are the most widely used anticoagulant drugs to treat patients
at risk of arterial and venous thrombosis for the past 50 years. Due to unfavorable …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …